Company Profile
Caribou Stock Price, News & Analysis
- Ticker:
- CRBU
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.59 USD (+1.27%)
Close
Last updated: July 27, 2026
230M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, CRBU closed up 1.27% at $1.59. No new same-company headline was identified in the current news window.
Company overview
Business overview
Caribou Biosciences is a gene-editing company focused on CRISPR-based cell therapies and oncology applications. The company is trying to make edited cell therapy more effective and scalable.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Caribou sits in advanced biotechnology.
Business Model Characteristics
The company depends on platform validation, clinical proof, and the ability to turn CRISPR-based cell therapy into a durable value driver.
Position Within the Biotechnology Landscape
Caribou is a high-catalyst gene-editing and cell-therapy name with strong sensitivity to clinical updates.
Future catalysts
Caribou’s catalysts are CB-010 and the rest of its allogeneic CAR-T pipeline, with persistence and safety being the main decision points. The company needs to show the off-the-shelf model still has room.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Caribou (CRBU)?
Caribou (CRBU) most recently closed at 1.59 USD, a +1.27% move versus the previous session.
What is the market cap of Caribou (CRBU)?
Caribou currently has a market capitalization of 230M USD on BioPharmSignal.
What does Caribou do?
Caribou Biosciences is a gene-editing company focused on CRISPR-based cell therapies and oncology applications. The company is trying to make edited cell therapy more effective and scalable.
On which exchange is CRBU stock listed?
Caribou (CRBU) is associated with NASDAQ, United States, Biopharma.
What is CB-010?
Caribou’s catalysts are CB-010 and the rest of its allogeneic CAR-T pipeline, with persistence and safety being the main decision points.
Which conditions is Caribou targeting with CB-010?
Caribou is associated with oncology based on its company overview and current catalyst commentary.
How does Caribou describe recent progress with CB-010?
Caribou’s catalysts are CB-010 and the rest of its allogeneic CAR-T pipeline, with persistence and safety being the main decision points.
What is CAR-T?
Caribou’s catalysts are CB-010 and the rest of its allogeneic CAR-T pipeline, with persistence and safety being the main decision points.